date,title,source
Oct-23-18,"Investor Expectations to Drive Momentum within Navios Maritime Partners LP, Alliance Data, Eli Lilly, CONVERGEONE HLD, Atkore International Group, and NantKwest  Discovering Underlying Factors of Influence",GlobeNewswire
Oct-23-18,NantKwest Sees Hammer Chart Pattern: Time to Buy?,Zacks
Nov-07-18,"NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine Immunotherapy",Business Wire
Nov-08-18,Here's Why NantKwest Skyrocketed 26.4% Today,Motley Fool
Nov-08-18,"Healthcare Stocks are Gaining Ground in Technology Niche: Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Inovalon Holdings, NantKwest Inc.",ACCESSWIRE
Dec-03-18,NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology,Business Wire
Dec-18-18,Is Nantkwest Inc (NK) Going to Burn These Hedge Funds?,Insider Monkey
Dec-25-18,"Have Insiders Been Selling NantKwest, Inc. (NASDAQ:NK) Shares?",Simply Wall St.
Jan-07-19,Soon-Shiongs NantCell gets $30 million from Celgene,American City Business Journals
Jan-09-19,NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNK Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy,Business Wire
Jan-10-19,Is the Options Market Predicting a Spike in NantKwest (NK) Stock?,Zacks
Feb-25-19,"Our Take On NantKwest, Inc.s (NASDAQ:NK) CEO Salary",Simply Wall St.
Mar-18-19,NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit,Business Wire
Mar-25-19,NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NKs Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy,Business Wire
Apr-01-19,NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate,Business Wire
Apr-01-19,Will NantKwest Continue to Surge Higher?,Zacks
May-23-19,"What Kind Of Investor Owns Most Of NantKwest, Inc. (NASDAQ:NK)?",Simply Wall St.
May-31-19,"NantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting",Business Wire
Jun-03-19,NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients,Business Wire
Jun-03-19,NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference,Business Wire
Jun-04-19,NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients,Business Wire
Jun-04-19,"NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics",Business Wire
Jun-06-19,Cheryl Cohen Appointed to NantKwests Board of Directors,Business Wire
